Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models
Autor: | S.K. Sarin, Hasmik Ghazinian, Guan Huei Lee, Abdülkadir Dökmeci, Padaki Nagaraja Rao, Viniyendra Pamecha, Wasim Jafri, Ajit Sood, Salimur Rahman, Gamal Shiha, Malay Sharma, JD Sollano, Zhongping Duan, Guresh Kumar, Chen Yu, Qin Ning, Harshad Devarbhavi, Sunil Taneja, Yogesh Chawla, Ji Dong Jia, Dong J Kim, Saeed Hamid, Rakhi Maiwall, Mamun Al Mahtab, Ashok Choudhury, Deepak Amarapurkar, Soek Siam Tan, Barjesh Chander Sharma, Pooja Jain, Chundamannil E. Eapen, G Carpio, Zaigham Abbas, AS Butt, Fazal Karim, Laurentius A. Lesmana, A. Jindal, D.A. Payawal, Richard Moreau, Ashish Goel, George K. K. Lau, Puja Bhatia |
---|---|
Rok vydání: | 2017 |
Předmět: |
medicine.medical_specialty
Cirrhosis Organ Dysfunction Scores Sensitivity and Specificity 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine medicine Humans Derivation Intensive care medicine Hepatic encephalopathy Creatinine Hepatology business.industry Liver failure Acute-On-Chronic Liver Failure Prognosis medicine.disease Survival Analysis Colorectal surgery chemistry 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology business Progressive disease |
Zdroj: | Hepatology International. 11:461-471 |
ISSN: | 1936-0541 1936-0533 |
DOI: | 10.1007/s12072-017-9816-z |
Popis: | Acute-on-chronic liver failure (ACLF) is a progressive disease associated with rapid clinical worsening and high mortality. Early prediction of mortality and intervention can improve patient outcomes. We aimed to develop a dynamic prognostic model and compare it with the existing models. A total of 1402 ACLF patients, enrolled in the APASL-ACLF Research Consortium (AARC) with 90-day follow-up, were analyzed. An ACLF score was developed in a derivation cohort (n = 480) and was validated (n = 922). The overall survival of ACLF patients at 28 days was 51.7%, with a median of 26.3 days. Five baseline variables, total bilirubin, creatinine, serum lactate, INR and hepatic encephalopathy, were found to be independent predictors of mortality, with AUROC in derivation and validation cohorts being 0.80 and 0.78, respectively. AARC-ACLF score (range 5–15) was found to be superior to MELD and CLIF SOFA scores in predicting mortality with an AUROC of 0.80. The point scores were categorized into grades of liver failure (Gr I: 5–7; II: 8–10; and III: 11–15 points) with 28-day cumulative mortalities of 12.7, 44.5 and 85.9%, respectively. The mortality risk could be dynamically calculated as, with each unit increase in AARC-ACLF score above 10, the risk increased by 20%. A score of ≥11 at baseline or persisting in the first week was often seen among nonsurvivors (p = 0.001). The AARC-ACLF score is easy to use, dynamic and reliable, and superior to the existing prediction models. It can reliably predict the need for interventions, such as liver transplant, within the first week. |
Databáze: | OpenAIRE |
Externí odkaz: |